| Objective:It aims to investigate that the effect on efficacy of blood lipid management,safety,and glucose metabolism for the treatment comparison between conventional rosuvastatin in conventional dosage and rosuvastatin combined with ezetimibe in conventional dosage in patients with ACS and IGT.Methods:From September 2017 to September 2018,a total of 180 patients with acute coronary syndrome and IGT who were admitted to Hospital of Traditional Chinese Medicine of Xinjiang Uyghur Autonomous Region within 48 hours were randomly divided into an observation group and a control group,with 90 patients in each group.Different lipid-lowing strategy was performed in two group,comparing the treatment in two groups as(1)Total cholesterol,low density lipoprotein cholesterol,high density lipoprotein cholesterol before treatment and after 6 months and 12 months of treatment;(2)If it appear during the 12 months of treatment:tumor diseases,creatine kinase elevation after medication>5×IU/L,transaminase elevation>3×IU/L,acute renal insufficiency,severe gastrointestinal reactions,proteinuria,allergic reactions,angioneuro-edema and other symptoms lead to drug discontinuance or replacement medicine.(3)The fasting blood glucose,2h blood glucose,glycated hemoglobin,and number of new onset diabetes after the 6~thh day of admission and 12 months of treatment.Results:There were no adverse reactions such as elevated liver enzymes of tumor,myopathy,acute renal insufficiency,proteinuria,gastrointestinal reactions,and allergic reactions in two groups.There was no significant difference in the TC,HDL-C,and LDL-C before treatment between the observation group and the control group(P>0.05);the levels of TC and LDL-C in the observation group after treatment for 6 months were 3.57±0.92 mmol/L and 1.99±0.60 mmol/L,while the control group was 4.17±0.9 mmol/L and 2.39±0.54 mmol/L,the value of TC and LDL-C in the two groups was statistically significant difference compared with that before treatment(P<0.05 in all indicators),the value of TC and LDL-C in the two groups was statistically significant difference compared with that after 12 months of treatment(P<0.05 in all indicators).After 6 months of treatment,the values of TC,HDL-C,and LDL-C were 3.01±1.06 mmol/L,1.32 0.28 mmol/L and 1.65±0.63 mmol/L in the observation group,while there were 3.93±0.84 mmol/L,1.09±0.30 mmol/L and 2.2±0.57mmol/L in control group,which was a statistical difference in two groups compared with before treatment(P<0.05 in all indicators),TC,HDL-C and LDL-C were statistical difference in the two groups after 12 months of treatment(P<0.05 in all indicators).There was no statistical difference of FBG,2hPPG,and HbAlc%between the observation group and the control group on the 6~thh day of admission(P>0.05 in all indicators),and there was no statistical difference in FBG,2hPPG,and HbAlc%between two groups after the 12months of treatment(P>0.05 in all indicators);there was no statistical difference of FBG and HbAlc%between after 12 months of treatment and on the 6~thh day of admission in the observation group(P>0.05 in all indicators),while there was a statistical difference of2hPPG(P<0.05);in the control group,the comparison was made.After 12 months,there was no statistical difference between FBG and HbAlc%on the 6~thh day of admission(both P>0.05),and there was a statistical difference between 2hPPG(P<0.05);there were 7 new onset diabetes patients in the treatment group,accounting for 7.8%,and 6 new onset diabetes patients in the control group,accounting for 6.7%,there was no statistical difference in the proportion of new-onset diabetes cases in the two groups(P>0.05).Conclusion:During a 12-month follow-up period,10 mg rosuvastatin combined with ezetimibe has a better lipid-lowering effect than 10 mg rosuvastatin,but there is no significant difference in safety and glucose metabolism. |
PDF Full Text Request